CERVOMED INC. - COMMON

12.53

07-November-24 15:59:45

15 minutes delayed

Stocks

-0.31

-2.41%

Today's range

12.43 - 13.30

ISIN

N/A

Source

NASDAQ

CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024

05 Mar 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed to Participate in the BIO CEO and Investor Conference

21 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies

12 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board

07 Feb 2024 08:30:00 By Nasdaq GlobeNewswire
CervoMed to Participate in the Emerging Growth Conference 67

05 Feb 2024 08:00:00 By Nasdaq GlobeNewswire
CervoMed to Participate in the Emerging Growth Conference 66

05 Jan 2024 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.